SCHOLAR ROCK HOLDING CORPORATION (SRRK) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 207.41M USD | Research and Development Expense |
| Revenue | 0.00 USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 75.66M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -406.36M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $207.41M | $0.00 | $75.66M | $-406.36M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $211.58M | (m) | $80.43M | $-409.57M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $208.44M | $0.00 | $75.60M | $-384.64M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $211.93M | (m) | $65.68M | $-362.11M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $210.16M | (m) | $57.00M | $-323.34M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $190.13M | (m) | $41.88M | $-270.73M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $184.55M | (m) | $36.63M | $-252.05M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $169.15M | (m) | $34.08M | $-230.73M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $150.76M | (m) | $31.63M | $-209.62M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $135.26M | (m) | $29.14M | $-189.21M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $121.90M | (m) | $27.14M | $-171.29M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $116.55M | (m) | $26.36M | $-163.69M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $119.61M | (m) | $27.07M | $-163.88M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $124.81M | (m) | $27.04M | $-167.95M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $124.44M | $33.19M | $27.70M | $-134.37M | (m) | 374.91% | 83.45% | (m) | (m) |
| 2022-09-30 | $123.88M | $37.24M | $27.63M | $-129.31M | (m) | 332.64% | 74.20% | (m) | (m) |
| 2022-06-30 | $121.75M | $42.71M | $25.87M | $-122.52M | (m) | 285.10% | 60.57% | (m) | (m) |
| 2022-03-31 | $115.28M | $47.30M | $25.30M | $-109.65M | (m) | 243.73% | 53.50% | (m) | (m) |
| 2021-12-31 | $108.47M | $18.82M | $23.15M | $-129.92M | (m) | 576.47% | 123.03% | (m) | (m) |
| 2021-09-30 | $101.20M | $18.20M | $19.58M | $-120.66M | (m) | 555.94% | 107.58% | (m) | (m) |
| 2021-06-30 | $88.31M | $15.78M | $17.46M | $-107.20M | (m) | 559.81% | 110.71% | (m) | (m) |
| 2021-03-31 | $79.71M | $15.08M | $13.63M | $-96.39M | (m) | 528.54% | 90.41% | (m) | (m) |
| 2020-12-31 | $74.06M | $15.40M | $11.18M | $-86.88M | (m) | 480.83% | 72.55% | (m) | (m) |
| 2020-09-30 | $66.35M | $19.54M | $10.50M | $-73.12M | (m) | 339.54% | 53.72% | (m) | (m) |
| 2020-06-30 | $63.66M | $21.28M | $9.15M | $-66.61M | (m) | 299.21% | 43.00% | (m) | (m) |
| 2020-03-31 | $60.38M | $22.42M | $8.57M | $-60.53M | (m) | 269.36% | 38.22% | (m) | (m) |
| 2019-12-31 | $54.22M | $20.49M | $7.97M | $-54.54M | (m) | 264.58% | 38.90% | (m) | (m) |
| 2019-09-30 | $50.28M | $12.92M | $8.27M | $-57.76M | (m) | 389.18% | 64.05% | (m) | (m) |
| 2019-06-30 | $42.64M | $8.14M | $7.07M | $-51.88M | (m) | 523.50% | 86.83% | (m) | (m) |
| 2019-03-31 | $40.35M | (m) | $6.35M | $-53.38M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $36.31M | $0.00 | $5.21M | $-50.69M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $19.94M | (m) | $1.48M | $-25.03M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |